Anders Helander research

Improved laboratory testing for alcohol and drugs of abuse – focus on alcohol biomarkers, illicit drugs, and new psychoactive substances (NPS, “Internet drugs”).

Early identification of individuals at risk for developing alcohol and drug-related problems may enable action to be initiated before serious symptoms occur and is a key factor for treatment success. People who abuse alcohol or recreational drugs seldom leave reliable information about their intake. Access to sensitive and specific objective measures (i.e. laboratory tests) for detection of short-term or long-term alcohol and drug use and to confirm abstinence is therefore important. This possibility was long limited by the lack of suitable analytes and/or detection methods.

Ethanol analysis in breath is a useful screening method for recent alcohol consumption but can only detect intake which occurred in the last couple of hours. Liver function tests such as GGT, on the other hand, will primarily identify heavy drinking which has been going on for months or years, which implies low sensitivity for early detection of harmful consumption. Another disadvantage of biomarkers of liver dysfunction is that elevated levels may be due to several causes besides heavy drinking (e.g. other liver disorders or medications).

The work has been focused on identifying, evaluating and implementing a new panel of clinically useful laboratory tests for alcohol. To detect drinking during the past days, measurement of the conjugated ethanol metabolites ethyl glucuronide (EtG) and ethyl sulfate (EtS) in urine is very useful, whereas for long-term alcohol consumption over the past few weeks to months, phosphatidylethanol (PEth) in whole blood and carbohydrate-deficient transferrin (CDT) in serum are the most specific tests.

Another problem in drug testing is that the large number of new psychoactive substances (NPS) introduced in recent years are not detected by current drug testing routines. A new testing strategy for NPS was therefore developed, based on liquid chromatography combined with high-resolution mass spectrometry (LC–HRMS), and has been implemented in routine use.

Other studies focus on using non-standard and less invasive biological matrices for routine alcohol and drug testing, such as oral fluid (“saliva”) and samples of exhaled breath. In parallel, new sensitive analytical methods are developed. The performance of new sample matrices and new test strategies in different patient populations and for different clinical and medico-legal purposes are also evaluated.

Researcher Anders Helander

Anders Helander

Adjunct senior lecturer
H5 Department of Laboratory Medicine

Research techniques

High-performance liquid chromatography, mass spectrometry, capillary electrophoresis (HPLC, LC-MS/MS, LC-HRMS, CE).

External funding

The Karolinska University Laboratory, Vinnova.

Selected publications

Measurement of the alcohol biomarker phosphatidylethanol (PEth) in dried blood spots and venous blood-importance of inhibition of post-sampling formation from ethanol.
Beck O, Mellring M, Löwbeer C, Seferaj S, Helander A
Anal Bioanal Chem 2021 Feb;():

Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project.
Helander A, Bäckberg M, Beck O
PLoS One 2020 ;15(4):e0232038

Dose-Response Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth)-A Study of Outpatients in Treatment for Reduced Drinking.
Helander A, Hermansson U, Beck O
Alcohol Alcohol. 2019 Dec;54(6):567-573

Elimination Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth) in Blood during Alcohol Detoxification.
Helander A, Böttcher M, Dahmen N, Beck O
Alcohol Alcohol. 2019 May;54(3):251-257

Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project.
Bäckberg M, Pettersson Bergstrand M, Beck O, Helander A
Clin Toxicol (Phila) 2019 03;57(3):203-212

The Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union.
Jannetto PJ, Helander A, Garg U, Janis GC, Goldberger B, Ketha H
Clin. Chem. 2019 02;65(2):242-253

Epidemiology of NPS Based Confirmed Overdose Cases: The STRIDA Project.
Helander A, Bäckberg M
Handb Exp Pharmacol. 2018 ;252():461-473

Intoxications involving acrylfentanyl and other novel designer fentanyls - results from the Swedish STRIDA project.
Helander A, Bäckberg M, Signell P, Beck O
Clin Toxicol (Phila) 2017 Jul;55(6):589-599

Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT).
Helander A, Wielders J, Anton R, Arndt T, Bianchi V, Deenmamode J, et al
Clin. Chim. Acta 2016 Aug;459():19-24


Content reviewer: